August Campaign Highlights Total Wellness for Over 8 Million in the U.S. with Psoriasis ALEXANDRIA, VA, UNITED STATES, August 1, 2025 /EINPres ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

Mentoring those newly diagnosed with psoriasis reminds a self-described old-timer of the value of lifestyle, community, and testing one’s limits.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Lower muscle volume, and more fat stored in the muscle, are seen linked to higher risk for disease and comorbidities.

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...

Researchers have found in a new research that deucravacitinib significantly improves joint pain and musculoskeletal symptoms ...

From eczema and psoriasis to arthritis and Parkinson’s, the appearance of our hands can tell us a lot about the state of our ...

A new study from scientists at Scripps Research suggests that a drug already approved by the FDA to treat inflammation could help people with alcohol use disorder (AUD) by reducing both alcohol ...

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated ...